Ildong Holdings Co., Ltd. (000230.KS)
KRW 6190.0
(0.0%)
KRW 6190.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 29.87 Billion KRW | -52.41% |
| 2022 | 62.78 Billion KRW | -23.74% |
| 2021 | 82.33 Billion KRW | 75.21% |
| 2020 | 46.99 Billion KRW | 75.75% |
| 2019 | 26.73 Billion KRW | 61907.89% |
| 2018 | 43.12 Million KRW | -28.57% |
| 2017 | 60.36 Million KRW | -99.8% |
| 2016 | 30.07 Billion KRW | -60.16% |
| 2015 | 75.49 Billion KRW | 11.7% |
| 2014 | 67.58 Billion KRW | 4.69% |
| 2013 | 64.56 Billion KRW | 201.7% |
| 2012 | 21.4 Billion KRW | 59.7% |
| 2011 | 13.4 Billion KRW | -65.76% |
| 2010 | 39.13 Billion KRW | -23.71% |
| 2009 | 51.3 Billion KRW | 61.32% |
| 2008 | 31.8 Billion KRW | 536.0% |
| 2007 | 5 Billion KRW | -56.52% |
| 2006 | 11.5 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 45.06 Billion KRW | 50.82% |
| 2024 Q2 | 32.6 Billion KRW | -27.64% |
| 2023 Q4 | 29.87 Billion KRW | -15.67% |
| 2023 Q1 | 50.37 Billion KRW | -19.77% |
| 2023 Q2 | 35.2 Billion KRW | -30.1% |
| 2023 FY | 29.87 Billion KRW | -52.41% |
| 2023 Q3 | 35.42 Billion KRW | 0.62% |
| 2022 Q3 | 80.56 Billion KRW | 1.28% |
| 2022 Q1 | 63.54 Billion KRW | -22.82% |
| 2022 FY | 62.78 Billion KRW | -23.74% |
| 2022 Q4 | 62.78 Billion KRW | -22.07% |
| 2022 Q2 | 79.54 Billion KRW | 25.17% |
| 2021 Q1 | 106.14 Billion KRW | 125.88% |
| 2021 FY | 82.33 Billion KRW | 75.21% |
| 2021 Q4 | 82.33 Billion KRW | 0.12% |
| 2021 Q3 | 82.23 Billion KRW | -14.99% |
| 2021 Q2 | 96.73 Billion KRW | -8.86% |
| 2020 Q2 | 29.9 Billion KRW | 6.49% |
| 2020 Q1 | 28.08 Billion KRW | 5.02% |
| 2020 FY | 46.99 Billion KRW | 75.75% |
| 2020 Q3 | 43.67 Billion KRW | 46.06% |
| 2020 Q4 | 46.99 Billion KRW | 7.59% |
| 2019 FY | 26.73 Billion KRW | 61907.89% |
| 2019 Q4 | 26.73 Billion KRW | -18.44% |
| 2019 Q2 | 2.14 Billion KRW | 10.53% |
| 2019 Q1 | 1.94 Billion KRW | 4406.31% |
| 2019 Q3 | 32.78 Billion KRW | 1426.41% |
| 2018 Q2 | 51.74 Million KRW | -7.69% |
| 2018 Q1 | 56.05 Million KRW | -7.14% |
| 2018 FY | 43.12 Million KRW | -28.57% |
| 2018 Q4 | 43.12 Million KRW | -9.09% |
| 2018 Q3 | 47.43 Million KRW | -8.33% |
| 2017 Q4 | 60.36 Million KRW | -6.67% |
| 2017 FY | 60.36 Million KRW | -99.8% |
| 2017 Q1 | 15.06 Billion KRW | -49.9% |
| 2017 Q2 | 15.06 Billion KRW | -0.03% |
| 2017 Q3 | 64.68 Million KRW | -99.57% |
| 2016 Q1 | 82.59 Billion KRW | 9.4% |
| 2016 Q4 | 30.07 Billion KRW | -16.64% |
| 2016 Q3 | 36.08 Billion KRW | 0.0% |
| 2016 Q2 | - KRW | -100.0% |
| 2016 FY | 30.07 Billion KRW | -60.16% |
| 2015 Q4 | 75.49 Billion KRW | 77.31% |
| 2015 FY | 75.49 Billion KRW | 11.7% |
| 2015 Q3 | 42.57 Billion KRW | -6.59% |
| 2015 Q2 | 45.58 Billion KRW | -24.77% |
| 2015 Q1 | 60.58 Billion KRW | -10.36% |
| 2014 FY | 67.58 Billion KRW | 4.69% |
| 2014 Q4 | 67.58 Billion KRW | -0.43% |
| 2014 Q3 | 67.88 Billion KRW | 5.79% |
| 2014 Q2 | 64.16 Billion KRW | 3.55% |
| 2014 Q1 | 61.96 Billion KRW | -4.03% |
| 2013 Q4 | 64.56 Billion KRW | 20.91% |
| 2013 FY | 64.56 Billion KRW | 201.7% |
| 2013 Q3 | 53.4 Billion KRW | -5.32% |
| 2013 Q1 | 23.4 Billion KRW | 9.35% |
| 2013 Q2 | 56.4 Billion KRW | 141.03% |
| 2012 FY | 21.4 Billion KRW | 59.7% |
| 2012 Q4 | 21.4 Billion KRW | 0.0% |
| 2012 Q1 | 13 Billion KRW | 0.0% |
| 2011 Q1 | 27 Billion KRW | 0.0% |
| 2011 Q2 | 27 Billion KRW | 0.0% |
| 2011 Q3 | 23 Billion KRW | -14.81% |
| 2011 FY | 13.4 Billion KRW | -65.76% |
| 2010 Q2 | 34 Billion KRW | 0.0% |
| 2010 Q3 | 24 Billion KRW | -29.41% |
| 2010 FY | 39.13 Billion KRW | -23.71% |
| 2009 Q4 | 37 Billion KRW | 29.82% |
| 2009 Q3 | 28.5 Billion KRW | 96.55% |
| 2009 FY | 51.3 Billion KRW | 61.32% |
| 2009 Q2 | 14.5 Billion KRW | 0.0% |
| 2008 Q4 | 11.5 Billion KRW | 15.0% |
| 2008 Q2 | 5 Billion KRW | 0.0% |
| 2008 Q3 | 10 Billion KRW | 100.0% |
| 2008 FY | 31.8 Billion KRW | 536.0% |
| 2007 FY | 5 Billion KRW | -56.52% |
| 2007 Q2 | 11.5 Billion KRW | 0.0% |
| 2007 Q4 | 5 Billion KRW | -23.08% |
| 2007 Q3 | 6.5 Billion KRW | -43.48% |
| 2006 FY | 11.5 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 26.007% |
| Yuhan Corporation | 60.23 Billion KRW | 50.399% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.036% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 85.214% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.411% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.411% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 58.569% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -61.3% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -184.539% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -6179.996% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 6.636% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 13.588% |
| Boryung Corporation | 151.7 Billion KRW | 80.307% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -393.829% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -57.017% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -4961.183% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -9630.019% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -137.414% |
| CKD Bio Corp. | 69.43 Billion KRW | 56.969% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 75.309% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 0.411% |
| Yuhan Corporation | 60.23 Billion KRW | 50.399% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13544.726% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.036% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1768.637% |
| HANDOK Inc. | 123.78 Billion KRW | 75.863% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 81.557% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 63.578% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -29243.231% |
| Suheung Co., Ltd. | 74 Billion KRW | 59.63% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -617.044% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.036% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -24864.095% |
| JW Holdings Corporation | 20.65 Billion KRW | -44.63% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -101.526% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.411% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -5045.411% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 39.727% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -571.083% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 68.017% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13544.726% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -172.535% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -85.251% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 61.953% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -393.829% |
| JW Lifescience Corporation | 168 Million KRW | -17683.708% |